- 米国企業
- Arbutus Biopharma Corp
Arbutus Biopharma CorpABUS
| 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Collaborations and licenses | - | - | - | - | - | - | 4 | 4 | 5 | 31 | 14 |
|---|
| Non-cash royalty revenue | - | - | - | - | - | - | - | 3 | 6 | 8 | 4 |
|---|
| Revenues | 15 | 15 | 25 | 1 | 11 | 6 | 6 | 7 | 11 | 39 | 18 |
|---|
| Research and development | 21 | 39 | 52 | 61 | 63 | 58 | 58 | 47 | 66 | 84 | 74 |
|---|
| General and administrative | 6 | 9 | 26 | 39 | 16 | 16 | 18 | 15 | 17 | 18 | 22 |
|---|
| Change in fair value of contingent consideration | - | - | 1 | 2 | 1 | -7 | -0 | 0 | 2 | 2 | 0 |
|---|
| Total operating expenses | 28 | 48 | 127 | 493 | 122 | 96 | 150 | 65 | 85 | 104 | 96 |
|---|
| Loss from operations | -12,153,218 | -33 | -102 | -492 | -111 | -90 | -144 | -58 | -74 | -65 | -78 |
|---|
| Interest income | 539,996 | 1 | 1 | 1 | 2 | 3 | 2 | 1 | 0 | 2 | 6 |
|---|
| Interest expense | - | - | - | - | 0 | 0 | 2 | 4 | 3 | 2 | 0 |
|---|
| Foreign exchange (loss) gain | 1 | 4 | 22 | 1 | 2 | -1 | 0 | -0 | 0 | -0 | 0 |
|---|
| Total other income | - | - | 25 | 2 | 2 | 28 | -22 | -6 | -3 | 0 | 5 |
|---|
| Loss before income taxes | - | - | - | - | - | - | - | - | - | -65 | -73 |
|---|
| Loss before income taxes | - | - | - | - | - | - | - | - | - | -65 | -73 |
|---|
| Income tax expense | - | - | -16 | -105 | -24 | -4 | -13 | - | - | 4 | - |
|---|
| Income tax expense | - | - | -16 | -105 | -24 | -4 | -13 | - | - | 4 | - |
|---|
| Net loss | -14,064,226 | -39 | -61 | -384 | -84 | -57 | -154 | -64 | -76 | -69 | -73 |
|---|
| Net loss | -14,064,226 | -39 | -61 | -384 | -84 | -57 | -154 | -64 | -76 | -69 | -73 |
|---|
| Basic (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Diluted (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Dividend accretion of convertible preferred shares | - | - | - | - | 1 | 10 | 11 | 12 | 12 | - | - |
|---|
| Net loss attributable to common shares | - | - | - | - | -85 | -67 | -165 | -76 | -88 | -69 | - |
|---|
| Unrealized loss on available-for-sale securities | - | - | - | - | - | - | - | 0 | -0 | -2 | - |
|---|
| Unrealized gain/(loss) on available-for-sale securities | - | - | - | - | - | - | - | - | - | - | 2 |
|---|
| Comprehensive loss | -17,198,972 | -45 | -89 | -384 | -84 | -57 | -154 | -64 | -76 | -72 | -71 |
|---|
| Basic (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Diluted (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Unrealized loss on available-for-sale securities | - | - | - | - | - | - | - | 0 | -0 | -2 | - |
|---|
| Unrealized gain/(loss) on available-for-sale securities | - | - | - | - | - | - | - | - | - | - | 2 |
|---|
| Comprehensive loss | -17,198,972 | -45 | -89 | -384 | -84 | -57 | -154 | -64 | -76 | -72 | -71 |
|---|
| Collaborations and licenses | - | - | - | - | - | - | 4 | 4 | 5 | 31 | 14 |
|---|
| Non-cash royalty revenue | - | - | - | - | - | - | - | 3 | 6 | 8 | 4 |
|---|
| Revenues | 15 | 15 | 25 | 1 | 11 | 6 | 6 | 7 | 11 | 39 | 18 |
|---|
| Research and development | 21 | 39 | 52 | 61 | 63 | 58 | 58 | 47 | 66 | 84 | 74 |
|---|
| General and administrative | 6 | 9 | 26 | 39 | 16 | 16 | 18 | 15 | 17 | 18 | 22 |
|---|
| Change in fair value of contingent consideration | - | - | 1 | 2 | 1 | -7 | -0 | 0 | 2 | 2 | 0 |
|---|
| Total operating expenses | 28 | 48 | 127 | 493 | 122 | 96 | 150 | 65 | 85 | 104 | 96 |
|---|
| Loss from operations | -12,153,218 | -33 | -102 | -492 | -111 | -90 | -144 | -58 | -74 | -65 | -78 |
|---|
| Interest income | 539,996 | 1 | 1 | 1 | 2 | 3 | 2 | 1 | 0 | 2 | 6 |
|---|
| Interest expense | - | - | - | - | 0 | 0 | 2 | 4 | 3 | 2 | 0 |
|---|
| Foreign exchange (loss) gain | 1 | 4 | 22 | 1 | 2 | -1 | 0 | -0 | 0 | -0 | 0 |
|---|
| Total other income | - | - | 25 | 2 | 2 | 28 | -22 | -6 | -3 | 0 | 5 |
|---|
| Loss before income taxes | - | - | - | - | - | - | - | - | - | -65 | -73 |
|---|
| Loss before income taxes | - | - | - | - | - | - | - | - | - | -65 | -73 |
|---|
| Income tax expense | - | - | -16 | -105 | -24 | -4 | -13 | - | - | 4 | - |
|---|
| Income tax expense | - | - | -16 | -105 | -24 | -4 | -13 | - | - | 4 | - |
|---|
| Net loss | -14,064,226 | -39 | -61 | -384 | -84 | -57 | -154 | -64 | -76 | -69 | -73 |
|---|
| Net loss | -14,064,226 | -39 | -61 | -384 | -84 | -57 | -154 | -64 | -76 | -69 | -73 |
|---|
| Basic (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Diluted (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Dividend accretion of convertible preferred shares | - | - | - | - | 1 | 10 | 11 | 12 | 12 | - | - |
|---|
| Net loss attributable to common shares | - | - | - | - | -85 | -67 | -165 | -76 | -88 | -69 | - |
|---|
| Unrealized loss on available-for-sale securities | - | - | - | - | - | - | - | 0 | -0 | -2 | - |
|---|
| Unrealized gain/(loss) on available-for-sale securities | - | - | - | - | - | - | - | - | - | - | 2 |
|---|
| Comprehensive loss | -17,198,972 | -45 | -89 | -384 | -84 | -57 | -154 | -64 | -76 | -72 | -71 |
|---|
| Basic (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Diluted (in USD per share) | -0.92 | -1.8 | -1.34 | -7.24 | -1.56 | -1.21 | - | - | -0.83 | -0.46 | -0.44 |
|---|
| Unrealized loss on available-for-sale securities | - | - | - | - | - | - | - | 0 | -0 | -2 | - |
|---|
| Unrealized gain/(loss) on available-for-sale securities | - | - | - | - | - | - | - | - | - | - | 2 |
|---|
| Comprehensive loss | -17,198,972 | -45 | -89 | -384 | -84 | -57 | -154 | -64 | -76 | -72 | -71 |
|---|